DB&C Advisors’s AbbVie ABBV Stock Holding History

DB&C Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.29M	Buy	21,009 +157	+0.8%	+$33.8K	5.72%	3
2026 Q1	$4.54M	Buy	20,852 +120	+0.6%	+$26.6K	5.89%	2
2025 Q4	$4.74M	Buy	+20,732	New	+$4.72M	5.94%	4

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

DB&C Advisors's ABBV Position: Q2 2026 in Review

DB&C Advisors increased its AbbVie (ABBV) stake by 0.75% in Q2 2026, buying an estimated $33.8K and bringing the position to 21,009 shares worth $5.29M. The position accounts for 5.72% of the portfolio, ranked #3.

DB&C Advisors first reported a position in ABBV in Q4 2025 and has held it in 3 quarters since. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

DB&C Advisors held 21,009 shares of AbbVie worth $5.29M as of Q2 2026.
DB&C Advisors bought 157 AbbVie shares in Q2 2026, an estimated $33.8K.
AbbVie made up 5.72% of DB&C Advisors's portfolio in Q2 2026, its #3 holding.
DB&C Advisors first reported a position in AbbVie in Q4 2025 and has held it in 3 quarters since.
4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on DB&C Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.